Health News Releases

  • Today May 22
October 28, 2014 21:00
KineMed and U.S. Army Announce Collaboration to Measure Muscle Function and Response During Military Operations
KineMed, Inc. and the U.S. Army Research Institute of Environmental Medicine’s (USARIEM) Military Nutrition Division announced today they are entering into a partnership to examine KineMed’s platform
October 28, 2014 13:50
Acelity Appoints Greg Kayata Senior Vice President, Human Resources
Acelity announced today that Greg Kayata has been named Senior Vice President, Human Resources, effective immediately. Greg replaces David Lillback, who announced earlier this year he will retire in N
October 22, 2014 11:40
Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments
For Ex-US and Ex-UK Media Only Boehringer Ingelheim today announced the enrolment of the first patient in a new global Phase III study in patients with advanced colorectal cancer (CRC). Colorectal
October 22, 2014 10:35
Many Koreans Underestimate Stroke, Would Miss Warning Signs Despite High Global Death Rate, Prevalence among Women
Despite its being the second leading cause of death worldwide, many people still do not recognize the threat stroke poses and the warning signs associated with it, according to a new public opinion st
October 21, 2014 13:35
GVK BIO Announces Successful Completion of Drug Repurposing Efforts to Identify Novel Indications
GVK Biosciences (GVK BIO, www.gvkbio.com), Asia’s leading integrated Discovery Research and Development organization, today announced the successful completion of in-silico based alternative indicatio
October 21, 2014 13:05
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of GED-0301
October 20, 2014 11:05
Clinical Trial at Kyoto Medical Center Proves Efficacy of Curcumin in Knee Osteoarthritis
The Orthopedics Division at National Hospital Organization, Kyoto Medical Center, announced that it has confirmed the efficacy of Theracrumin®, absorption enhanced curcumin*1 on knee osteoarthritis, b
October 17, 2014 17:45
Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis
For media outside UK, US and Canada Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved OFEV™ (nintedanib*) for the treatment of idiopathic pulmonary fi
October 17, 2014 15:35
Xagenic Appoints Timothy I. Still as President & Chief Executive Officer
Xagenic, a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, today announced the appointment of Timothy I. Still as President a
October 16, 2014 20:25
REMINDER: 22nd Century Group to Ring the New York Stock Exchange Closing Bell - Today at 4pm EDT
22nd Century Group, Inc. (NYSE MKT:XXII) announced today that Joseph Pandolfino, Founder and CEO of 22nd Century Group, together with other members of senior management, will ring The Closing Bell® at
October 16, 2014 11:35
22nd Century Group to Ring the New York Stock Exchange Closing Bell
22nd Century Group, Inc. (NYSE MKT:XXII, www.xxiicentury.com/irtools) announced today that Joseph Pandolfino, Founder and CEO of 22nd Century Group, together with other members of senior management, w
October 15, 2014 11:45
Quintiles Wins Society for Clinical Research Sites’ 2014 Eagle Award
Quintiles today announced that the company was awarded the Society for Clinical Research Sites’ (SCRS) 2014 Clinical Research Organization (CRO) Eagle Award. The award, which recognizes outstanding le
Director Seo Hyo-seok delivered his “Free from Chemical Medicine” speech.
October 15, 2014 09:00
“Steroids OUT!” A Korean Medicine Doctor Banning Chemical Medicine
About 123,000 patients with atopic dermatitis, rhinitis, and asthma and 32,000 patients with pulmonary emphysema, bronchiectasis, and pulmonary fibrosis have been cured.” There is a Korean medicine
October 13, 2014 13:45
Covidien Promotes Greater Global Awareness of Thrombosis Risks
As part of a global effort to highlight the threat posed by venous thromboembolism (VTE), Covidien plc today announced it will support the inaugural World Thrombosis Day campaign as a Global Partner.
October 13, 2014 11:40
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from additional efficacy and safety analyses of OTEZLA® (apremilast) from the E
October 13, 2014 11:35
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that patient-reported health outcomes data for OTEZLA® (apremilast) were presented at the 23
October 10, 2014 13:30
ERYTECH wins EuropaBio’s Most Innovative European Biotech SME Award 2014
Regulatory News: ERYTECH (Paris:ERYP)(Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other
October 08, 2014 13:45
PrIME Biologics Announces SGD16M in Equity Funding Led by Xeraya Capital
PrIME Biologics Private Limited today announced investments from Xeraya Capital Labuan Ltd via its affiliate, Pulau Manukan Ventures Labuan Ltd, and JP Asia Prime Capital Pte Ltd. This investment w
October 06, 2014 14:30
Galderma Initiates U.S. Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgery
Galderma, a global healthcare company focused on dermatology, today announced that it has initiated a Phase II clinical trial of a novel muscle relaxant in the United States. The study is investigatin
October 06, 2014 14:00
Arbonne International Opens for Business in Poland
Arbonne International, LLC (Arbonne) through its subsidiary Arbonne Europe Sarl, officially opens its business in Poland today, marking the 34-year-old company’s entry into continental Europe. With th
October 02, 2014 16:25
EDP Biotech Announces CE Mark Approval for ColoMarker an in Vitro Diagnostic Aid in Early Detection of Colon Cancer and Plans for Commercialization in Europe
EDP Biotech Corporation (www.edpbiotech.com), (“EDP,” or the “Company”), a global in vitro diagnostic innovator of life-saving, easy-to-use cancer diagnostic tests using ELISA technology, has announce
September 30, 2014 15:15
Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma
Seattle Genetics, Inc. (www.seattlegenetics.com) (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that patients with Hodgkin lymphoma (HL) who received ADCETRIS (bre
September 29, 2014 19:20
AZD9291 Shows Durable Clinical Response in Patients with Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer at the ESMO 2014 Congress
Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth fact
September 29, 2014 16:30
Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung
For Ex-US and Ex-UK Media Only Phase III data from Boehringer Ingelheim’s LUX-Lung 8 (http://goo.gl/gLcQzS) trial, the first study to directly compare the efficacy of two different targeted agents
September 29, 2014 16:15
Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung
For media outside UK and US only Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opi
25 per page50 per page75 per page100 per page